Verve Therapeutics Inc - Asset Resilience Ratio
Verve Therapeutics Inc (VERV) has an Asset Resilience Ratio of 65.21% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See VERV net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Verve Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see VERV total assets.
Liquid Assets Composition Over Time
This chart breaks down Verve Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Verve Therapeutics Inc debt and liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $400.52 Million | 65.21% |
| Total Liquid Assets | $400.52 Million | 65.21% |
Asset Resilience Insights
- Very High Liquidity: Verve Therapeutics Inc maintains exceptional liquid asset reserves at 65.21% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Verve Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Verve Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
F:A71 |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 2.58% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Kailera Therapeutics, Inc. Common Stock
NASDAQ:KLRA |
Biotechnology | 64.92% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 78.22% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
Annual Asset Resilience Ratio for Verve Therapeutics Inc (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Verve Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 54.33% | $351.72 Million | $647.39 Million | -1.17pp |
| 2023-12-31 | 55.50% | $417.77 Million | $752.69 Million | -9.19pp |
| 2022-12-31 | 64.69% | $439.40 Million | $679.22 Million | -12.40pp |
| 2021-12-31 | 77.09% | $296.11 Million | $384.12 Million | -3.41pp |
| 2020-12-31 | 80.50% | $63.12 Million | $78.41 Million | +7.52pp |
| 2019-12-31 | 72.97% | $15.80 Million | $21.65 Million | -- |
About Verve Therapeutics Inc
Verve Therapeutics, Inc., a clinical-stage company, develops gene editing medicines for patients to treat cardiovascular disease in the United States. The company's product candidates include VERVE-101, which is being evaluated in the Heart-1 trial, an open-label Phase 1b clinical trial, as well as changes in blood PCSK9 protein and LDL-C levels in patients living with heterozygous familial hyper… Read more